Company news

Cytosorbents Corporation (NASDAQ:CTSO) news

Cytosorbents Corporation news releases on 6ix. Latest, Sep 30, 2026: CytoSorbents Announces New Data Presentations at Upcoming International Conferences…

Cytosorbents Corporation (NASDAQ:CTSO) news

Press releases & updates

CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care

CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care

CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement

CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference

CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

CytoSorbents Announces Reverse Stock Split

CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings

CytoSorbents : Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

Cytosorbents : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)

CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights

CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026

CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights

CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026

CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update

CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025

Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London

CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update

CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London

CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights

In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer

CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen

CytoSorbents Provides DrugSorb-ATR Regulatory Update

CytoSorbents To Host Global Webinar on "Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb" in Recognition of World Sepsis Day

CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference

CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR

CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update

CytoSorbents Leads a New Era in Sepsis Treatment

CytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights

CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR

CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR

CytoSorbents to Participate at the Jefferies Global Healthcare Conference

CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025

CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update

CytoSorbents Provides Regulatory Update for DrugSorb-ATR

CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights

CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program

CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller

CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America

CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants

CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit

CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller

CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants

CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering

CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai

CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue